Henry Schein - HSIC Stock Forecast, Price & News

Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products comprising branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners. This segment also provides value-added practice solutions, which comprise financial services on a non-recourse basis, e-services, practice technology, network, and hardware services, as well as continuing education services for practitioners, and consulting and other services. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Piper Sandler reduced their price target on Henry Schein from $100.00 to $96.00 in a research report on Tuesday, August 2nd. StockNews.com cut Henry Schein from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, July 19th. Credit Suisse Group reduced their price objective on shares of Henry Schein from $100.00 to $90.00 and set an "outperform" rating for the company in a research note on Wednesday. Robert W. Baird lowered shares of Henry Schein from an "outperform" rating to a "neutral" rating and decreased their target price for the stock from $103.00 to $88.00 in a report on Tuesday, June 14th. Finally, Barrington Research reduced their price target on shares of Henry Schein from $102.00 to $99.00 and set an "outperform" rating for the company in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $87.14.

Henry Schein Price Performance

Shares of NASDAQ:HSIC traded up $1.23 during trading on Friday, reaching $75.38. The company had a trading volume of 659,650 shares, compared to its average volume of 765,484. The company has a fifty day moving average of $77.98 and a two-hundred day moving average of $82.02. The company has a current ratio of 1.83, a quick ratio of 0.91 and a debt-to-equity ratio of 0.18. The stock has a market capitalization of $10.26 billion, a P/E ratio of 16.18, a price-to-earnings-growth ratio of 2.03 and a beta of 0.75. Henry Schein has a 12 month low of $70.25 and a 12 month high of $92.68.

Henry Schein (NASDAQ:HSIC - Get Rating) last posted its quarterly earnings results on Tuesday, August 2nd. The company reported $1.16 earnings per share for the quarter, hitting the consensus estimate of $1.16. The business had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.12 billion. Henry Schein had a net margin of 5.11% and a return on equity of 15.56%. The firm's revenue for the quarter was up 2.1% on a year-over-year basis. During the same period in the previous year, the firm posted $1.11 earnings per share. Equities research analysts forecast that Henry Schein will post 4.85 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Gerald A. Benjamin sold 11,489 shares of the business's stock in a transaction dated Thursday, May 26th. The shares were sold at an average price of $85.47, for a total transaction of $981,964.83. Following the sale, the executive vice president now owns 95,616 shares of the company's stock, valued at $8,172,299.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.00% of the stock is owned by insiders.